Target intelligence / Profile preview

Antigen presentation pathway via antigen-presenting cell

Molecular classification
Other
01

Overview

The **antigen presentation pathway via antigen-presenting cell (APC)** refers to the multi-step immunological process by which specialized cells known as antigen-presenting cells (mainly dendritic cells, macrophages, and B cells) process protein antigens and display the resulting peptide fragments on their cell surface bound to major histocompatibility complex (MHC) molecules[1][2][3][4]. This surface presentation allows T cells to recognize these peptides through their T cell receptors (TCRs), initiating tailored adaptive immune responses crucial for the control of infections, response to neoplastic cells, and the regulation of immune tolerance[1][3]. There are two main branches of the pathway: MHC class I (presenting intracellular antigens to cytotoxic T cells) and MHC class II (presenting extracellular antigens to helper T cells); both are essential for the immune system’s ability to distinguish self from non-self and to mount an appropriate defense against pathogens and malignant cells[2][3][4]. Disruptions, defects, or dysregulation in this pathway are implicated in a variety of disease contexts, including infections, cancers, and autoimmune disorders[1][3][4].\n\nNotes on "is_target" and "is_incorrect":\n- **This is not a single molecular target** (such as a receptor or enzyme), but a complex cellular pathway involving multiple proteins (MHC molecules, proteasomes, transporters, co-receptors, etc.) and cell types. Therefore, **it is not considered a "therapeutic target"** in the molecular sense, though many drugs or biologics may modulate components of this pathway or the activity of APCs[1][2][4].\n- The entry is somewhat incorrect as a target: "Antigen presentation pathway via APCs" refers to a process or pathway, not a molecule, receptor, or specific druggable target. Individual proteins within this pathway (such as MHC class I or II molecules) can be considered molecular targets[1][3][4].

Other names
antigen presentation pathwayantigen processing and presentationantigen presentation via APCMHC-mediated antigen presentation
02

Biological functions

Immune responseT cell activationAdaptive immunity
03

Disease associations

InfectionCancerAutoimmune disease

Beyond the preview

Go deeper on Antigen presentation pathway via antigen-presenting cell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Antigen presentation pathway via antigen-presenting cell.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call